Voyager Therapeutics Inc stock PB Ratio (=1.42) is close to 2-year low of 1.39
The historical rank and industry rank for Voyager Therapeutics's PB Ratio or its related term are showing as below:
VYGR'
s PB Ratio Range Over the Past 10 Years
Min: 0.98 Med: 2.6 Max: 13.7
Current: 1.42
During the past 11 years, Voyager Therapeutics's highest PB Ratio was 13.70. The lowest was 0.98. And the median was 2.60.
VYGR's PB Ratio is ranked better than 70.31% of 1310
companies
in the Biotechnology industry
Industry Median: 2.375
vs VYGR: 1.42
During the past 12 months, Voyager Therapeutics's average Book Value Per Share Growth Rate was 251.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.40% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Voyager Therapeutics was 20.40% per year. The lowest was -40.40% per year. And the median was -9.10% per year.
Back to Basics: PB Ratio
Voyager Therapeutics PB Ratio Historical Data
The historical data trend for Voyager Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Voyager Therapeutics's PB Ratio
For the Biotechnology subindustry, Voyager Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's PB Ratio falls into.
Voyager Therapeutics PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Voyager Therapeutics (NAS:VYGR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Voyager Therapeutics PB Ratio Related Terms
Thank you for viewing the detailed overview of Voyager Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Voyager Therapeutics (Voyager Therapeutics) Business Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VYGR has been successfully added to your 